CA-CEPTON/ALP.LAB
22.2.2021 14:02:12 CET | Business Wire | Press release
Cepton, a leading provider of intelligent, lidar-based solutions, and the Austrian Industry and Testing Alliance ALP.Lab have partnered to build lidar-equipped testing environments for studying complicated road driving situations. For the first time in Austria, this project will deliver real-world traffic data from complex urban and rural alpine intersections.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005304/en/
As an alliance of automotive suppliers such as Magna and AVL, and as a partner to scientific organizations like Virtual Vehicle Research, Joanneum Research and Graz University of Technology, ALP.Lab delivers real-life data on complex traffic situations to test the capabilities of the autonomous driving systems, and helps enable solutions to reduce accidents and improve traffic flows.
From narrow, foggy streets covered in snow, to cyclists overtaking a tram in the middle of an intersection, Austria, with its mountainous landscape, sees varied road driving scenarios and faces unique challenges in ensuring vehicle and pedestrian safety. Difficult traffic scenarios could pose obstacles for the seamless deployment of autonomous mobility solutions. Compiling a realistic database of different driving scenarios is, therefore, pivotal to the testing and verification of advanced driver assistance systems (ADAS) and autonomous vehicles (AVs), to ensure that they work well in complex environments.
Through this new partnership, ALP.Lab has deployed Cepton’s Helius™ Smart Lidar System to capture real-time, 3D traffic data to support the training of artificial intelligence (AI) algorithms used for the scenario-based testing of ADAS and AV features. Additionally, the collected data will make it possible to predict vehicle trajectories at intersections and enable traffic data analysis for traffic flow optimization.
As part of the Helius system, a number of Vista®-P60 lidar sensors from Cepton have been installed at the corners of road intersections and traffic roundabouts, complementing other sensor types including radar and other types of optical sensors. For traffic monitoring and analysis applications, lidars perform well in many critical cases where other sensor types struggle. Lidars offer 24/7 availability thanks to their superior perception capabilities in various lighting conditions, such as night-time, shadows and the glare of strong headlights. Lidars also offer much higher angular resolution compared to radars and minimize false negatives and false positives. The Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), offer a high detection range of 200 m at 30% reflectivity and an angular resolution of 0.25°, making it possible to accurately detect each arriving and departing vehicle and pedestrian at a distance of up to ~170 meters around the intersections.
The advanced Helius perception software adds an additional layer of intelligence to the lidar data from the Vista-P60. Helius takes the point cloud data from a connected network of Vista-P60 sensors and delivers real-time, 3D information on object dimensions, locations and velocities. This enables Helius to accurately track and classify the different objects involved in a traffic situation. As Helius and the other sensors used by ALP.Lab only capture anonymized data, it protects the privacy of pedestrians and vehicles while feeding ALP.Lab rich traffic data for deeper analysis.
The Helius Smart Lidar system offers optimal ease of integration. The rotation-free, mirrorless and frictionless design makes Vista-P60 sensors very durable and embeddable. The rugged sensor housing is designed to withstand harsh outdoor environments and cold climates, resulting in product robustness and longevity to drive down maintenance costs. With the pre-installed Helius software running on an edge computer, which connects a scalable network of lidar sensors, Helius is a truly plug-and-play system that is extremely easy to set up and scale up.
“We primarily selected Cepton's lidar solutions because of their durability and precise detection capabilities even at high vehicle speeds. With the information the lidar sensors provide, our data is as close to real-life as it gets. Therefore, we are able to create enhanced simulation and AV testing environments as well as detailed analyses of the traffic flow,” said Christian Schwarzl, Director of Testing and Validation from ALP.Lab. “There is amazing synergy between Cepton and ALP.Lab, as we share the same goal of making ADAS and AV features available to the mass market and to improve the safety of vulnerable road users.”
“Lidar plays a crucial role in the future of autonomous mobility, by not only serving as the 'eyes' of vehicles but also bringing intelligence to the traffic infrastructure supporting safe autonomy. In order to make ADAS and AV capabilities available to the broader public, it is crucial to gather information on traffic scenarios that all vehicles are likely to be confronted with, in order to generate proper testing environments and ensure safer roads,” said Dr. Jun Pei, CEO of Cepton. “So, we are excited to partner with ALP.Lab in this endeavor, and we are gratified that our technology can contribute significantly to its success.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About ALP.Lab
ALP.Lab is the Austrian Light Vehicle Proving Region for Automated Driving and provides comprehensive services for safe and secure testing of automated driving technologies.
Founded in 2017, ALP.Lab provides an integrated test chain for automated driving functions and vehicles, enabling testing activities in both the virtual and real world. ALP.Lab offers a holistic traffic monitoring solution to create testing scenarios out of real-life driving behavior in primary, secondary, and urban road networks. Further, ALP.Lab provides a professional testing team for Euro-NCAP-compliant ADAS/AD testing, including extensive testing equipment and different proving grounds. A unique mobile HIL (hardware-in-the-loop) system facilitates complex sensor testing and validation.
A strong network of industrial and scientific partners support the capabilities of ALP.Lab for safe and secure testing of any autonomous mobility solutions. Creating value for their customers by providing high-end testing facilities and real-time traffic data is the main driver for the Austrian Light Vehicle Proving Region for Automated Driving.
For more information, visit www.alp-lab.at and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005304/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom